In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma

Overview

Journal Gastro Hep Adv

Specialty Gastroenterology

Date 2022 Sep 19

PMID 36117551

Authors

A M Vazquez Salgado

M E Preziosi

D Yin

A Holczbauer

A M Zahm

N Erez

J Kieckhaefer

D Ackerman

T P Gade

K H Kaestner

K J Wangensteen

Affiliations

Soon will be listed here.

Citing Articles

Pivotal role of intestinal cholesterol and nuclear receptor LXR in metabolic liver steatohepatitis and hepatocarcinoma.

Piccinin E, Arconzo M, Pasculli E, Tricase A, Cultrera S, Bertrand-Michel J Cell Biosci. 2024; 14(1):69.

PMID: 38824560 PMC: 11144344. DOI: 10.1186/s13578-024-01248-y.

Emerging and potential use of CRISPR in human liver disease.

Adlat S, Vazquez Salgado A, Lee M, Yin D, Wangensteen K Hepatology. 2023; .

PMID: 37607734 PMC: 10881897. DOI: 10.1097/HEP.0000000000000578.

An extended transcription factor regulatory network controls hepatocyte identity.

Dubois-Chevalier J, Gheeraert C, Berthier A, Boulet C, Dubois V, Guille L EMBO Rep. 2023; 24(9):e57020.

PMID: 37424431 PMC: 10481658. DOI: 10.15252/embr.202357020.

Lipid Nanoparticle Delivery of Small Proteins for Potent RAS Inhibition.

Haley R, Chan A, Billingsley M, Gong N, Padilla M, Kim E ACS Appl Mater Interfaces. 2023; 15(18):21877-21892.

PMID: 37115558 PMC: 10727849. DOI: 10.1021/acsami.3c01501.

References

Long H, Guo X, Qiao S, Huang Q . Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular Carcinoma. Pathol Oncol Res. 2017; 24(2):339-344. DOI: 10.1007/s12253-017-0249-8. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Shao W, Zhu W, Lin J, Luo M, Lin Z, Lu L . Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR. Neoplasia. 2019; 22(1):1-9. PMC: 6911865. DOI: 10.1016/j.neo.2019.08.002. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Rudalska R, Harbig J, Snaebjornsson M, Klotz S, Zwirner S, Taranets L . LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer. 2022; 2(2):201-217. DOI: 10.1038/s43018-020-00168-3. View